![](https://endpts.com/wp-content/uploads/2017/03/protocols-endpoints-news.jpg)
Ocular cuts staff in wake of FDA slapdown; Biogen recruits Pfizer vet; X4 inks discovery deal with Yale
→ Just days after its bid to salvage its second application for the drug/device eye therapy Dextenza failed with another slapdown by regulators, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.